FREQUENCY AND COSTS ASSOCIATED WITH TARGETED THERAPY-RELATED ADVERSE EVENTS (AES) DURING FIRST AND SECOND LINE OF TREATMENT (LOT) AMONG PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC)

被引：0
|
作者：
Byfield, DaCosta S. [1 ]
Langer, C. [2 ]
Ogale, S. [2 ]
Morlock, R. [2 ]
机构：
[1] Optum, Eden Prairie, MN USA
[2] Genentech Inc, San Francisco, CA 94080 USA
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN75
引用
收藏
页码：A80 / A81
页数：2
相关论文
共 50 条
  • [31] Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC)
    Rivera Herrero, F.
    Bachet, J-B.
    Modest, D. P.
    de Braud, F.
    Pietrantonio, F.
    Koukakis, R.
    Demonty, G.
    Douillard, J-Y.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [32] Machine-Learning Based Risk Assessment for Cancer Therapy-Related Cardiac Adverse Events Among Breast Cancer Patients
    Nguyen, Quynh T. N.
    Phan, Phuc T.
    Lin, Shwu-Jiuan
    Hsu, Min-Huei
    Li, Yu-Chuan
    Hsu, Jason C.
    Nguyen, Phung-Anh
    [J]. MEDINFO 2023 - THE FUTURE IS ACCESSIBLE, 2024, 310 : 1006 - 1010
  • [33] ESTIMATION OF COSTS OF FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER (MCRC) WITH FOLFIRI, FOLFOX OR XELOX PLUS BEVACIZUMAB, IN FIVE MEXICAN INSTITUTIONS
    Calderillo, Ruiz G.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A539 - A539
  • [34] Second line chemotherapy after first line irinotecan, oxaliplatin and 5-FU/LV (FOLFOXIRI) in metastatic colorectal cancer (MCRC) patients (pts).
    Masi, G
    Allegrini, G
    Marcucci, L
    Cupini, S
    Brunetti, I
    Fontana, E
    Ricci, S
    Cerri, E
    Barbara, C
    Falcone, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 291S - 291S
  • [35] Survival and Lifetime Costs Associated With First-Line Bevacizumab Use in Older Patients With Metastatic Colorectal Cancer
    Shankaran, Veena
    Mummy, David
    Koepl, Lisel
    Bansal, Aaasthaa
    Mirick, Dana K.
    Yu, Elaine
    Morlock, Rob
    Ogale, Sarika
    Ramsey, Scott D.
    [J]. ONCOLOGIST, 2014, 19 (08): : 892 - 899
  • [36] COMPREHENSIVE INVESTIGATION OF ADVERSE EVENT (AE)-RELATED COSTS IN PATIENTS WITH METASTATIC BREAST CANCER (MBC) TREATED WITH FIRST- AND SECOND-LINE CHEMOTHERAPIES
    Hurvitz, S. A.
    Guerin, A.
    Brammer, M.
    Guardino, E.
    Zhou, Z. Y.
    Kaminsky, M. S.
    Wu, E. Q.
    Lalla, D.
    [J]. VALUE IN HEALTH, 2012, 15 (07) : A418 - A418
  • [37] EPIDEMIOLOGY PROJECTION TRENDS FOR METASTATIC COLORECTAL CANCER (MCRC) PATIENTS RECEIVING SECOND LINE (2L) THERAPY IN EU AND US
    Moulard, O.
    Mehta, J.
    Naoshy, S.
    Olivares, R.
    Iqbal, S. U.
    Chau, I.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 213 - 214
  • [38] Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies
    Hurvitz, Sara A.
    Guerin, Annie
    Brammer, Melissa G.
    Guardino, Ellie
    Zhou, Zheng-Yi
    Kaminsky, Michael S.
    Wu, Eric Q.
    Lalla, Deepa
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Healthcare costs and resource utilization associated with select severe adverse events in patients with metastatic urothelial cancer treated with first-line systemic therapies
    Shenolikar, Rahul
    Laliberte, Francois
    Doleh, Yunes
    Cavanaugh, Cristi
    DerSarkissian, Maral
    Grivas, Petros
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 300 - 301
  • [40] Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment
    L Bennett
    Z Zhao
    B Barber
    X Zhou
    M Peeters
    J Zhang
    F Xu
    J Wiezorek
    J-Y Douillard
    [J]. British Journal of Cancer, 2011, 105 : 1495 - 1502
12345